Ansun BioPharma secures $85m to advance experimental anti-viral
Ansun BioPharma is working with FDA to plan and implement a Ph III clinical trial of its experimental anti-viral medication, DAS181.
Archives for May 16, 2018
Experts warn: If Europe doesn’t innovate, it will lose manufacturing to pharmerging countries
An Irish-led initiative will advocate for regulatory change to secure and sustain the pharmaceutical manufacturing sector in Europe.
Pfizer collects its third US FDA biosimilar approval with Retacrit
The FDA has approved Pfizer’s Retacrit, a biosimilar alternative to Amgen’s Epogen and J&J’s Procrit, which the company will price at a "significant discount."
TapImmune, Marker merger to ‘significantly disrupt’ CAR-T and TCR field, says CEO
TapImmune CEO says Marker Therapeutics’ data could be game-changing, as the two companies set to merge and disrupt the field of immuno-oncology and cell therapy.